1. Home
  2. IMRN vs CYCN Comparison

IMRN vs CYCN Comparison

Compare IMRN & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.77

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Logo Cyclerion Therapeutics Inc.

CYCN

Cyclerion Therapeutics Inc.

HOLD

Current Price

$1.34

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMRN
CYCN
Founded
1994
2018
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.2M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
IMRN
CYCN
Price
$0.77
$1.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
20.2K
57.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$1.03
52 Week High
$2.38
$3.79

Technical Indicators

Market Signals
Indicator
IMRN
CYCN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
IMRN
CYCN

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: